Astellas/Cardiome Anticipate Oct. 19 Vernakalant User Fee Date
This article was originally published in PharmAsia News
Astellas Pharma and Cardiome Pharma anticipate an Oct. 19, 2007, user fee date for vernakalant (RSD1235), an intravenous formulation for acute conversion of atrial fibrillation, based upon a 10-month standard FDA review. Astellas resubmitted the NDA for vernakalant Dec 19
You may also be interested in...
Sanofi-Aventis' resubmission of the atrial fibrillation medication Multaq is expected to include data from the ongoing ATHENA trial.
Revised agreement is a show of “confidence” following FDA’s refusal to file the original application for RSD1235.
Cardiome says a third quarter resubmission of its anti-arrhythmic product will not require additional clinical data.